Source comparison
Tesamorelin + Ipamorelin Blend Men Over 40: Protocol Comparison
Tesamorelin + Ipamorelin Blend Tesamorelin 1–2mg AM; Ipamorelin 200–300mcg twice daily Dual GHRH + ghrelin receptor activation; restores pulse amplitude and frequency 12–18% (MRI-measured visceral adipose area) Sustained 18–24 hours; 200–280 ng/mL range Optima
This comparison does not assign a generated winner or score.
- Tesamorelin + Ipamorelin Blend
- Tesamorelin 1–2mg AM; Ipamorelin 200–300mcg twice daily
- Dual GHRH + ghrelin receptor activation; restores pulse amplitude and frequency
- 12–18% (MRI-measured visceral adipose area)
- Sustained 18–24 hours; 200–280 ng/mL range
- Optimal for men over 40 targeting visceral fat with preserved lean mass; requires consistent dosing and proper storage
- Tesamorelin Monotherapy
- 2mg daily, morning injection
- GHRH analogue; pituitary growth hormone release
- 8–12%
- Moderate; 150–200 ng/mL range
- Proven visceral fat efficacy but lacks ipamorelin's anabolic signaling; better tolerated in subjects sensitive to ghrelin receptor effects
- Ipamorelin Monotherapy
- 200–300mcg 2–3x daily
- Selective ghrelin receptor agonist; pulsatile GH secretion
- 5–8%
- Short-duration peaks; less sustained elevation
- Strong lean mass preservation; minimal visceral fat specificity without GHRH component; ideal for body recomposition in leaner individuals
- CJC-1295 + Ipamorelin
- CJC-1295 (no DAC) 100–200mcg + Ipamorelin 200–300mcg, 1–2x daily
- GHRH analogue with extended half-life + ghrelin receptor agonist
- 10–14%
- Sustained; longer half-life than tesamorelin
- Comparable efficacy; CJC-1295 half-life (6–8 days) allows less frequent dosing but may increase side effect risk in peptide-naïve users
- Sermorelin + Ipamorelin
- Sermorelin 200–300mcg + Ipamorelin 200–300mcg, twice daily
- GHRH analogue (shorter half-life) + ghrelin receptor agonist
- 6–10%
- Moderate; shorter duration than tesamorelin or CJC-1295
- Gentler option for initial protocols; lower potency per injection requires more frequent dosing; reduced risk of desensitization
- Bottom Line / Professional Assessment
- Tesamorelin + ipamorelin blend is the evidence-backed standard for men over 40 targeting visceral adipose reduction. Tesamorelin's clinical validation in visceral fat trials combined with ipamorelin's selective anabolic signaling addresses both fat loss and lean mass preservation without cortisol or prolactin elevation. CJC-1295 + ipamorelin offers comparable efficacy with less frequent dosing but longer systemic exposure. Sermorelin combinations suit peptide-naïve users prioritizing tolerability over maximum efficacy. Single-peptide protocols address only one pathway—acceptable for narrower goals but suboptimal for comprehensive body recomposition in aging male populations.